Literature DB >> 6768447

Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma.

M M Wick.   

Abstract

Levodopa and dopamine are naturally occurring catecholamines with antitumor activity in several experimental tumor systems. Previous studies suggested that their cytotoxic effect was related in part to their inhibitory effect upon DNA polymerase. We have examined the effects of levodopa, dopamine, levodopa methyl ester, norepinephrine, and the analog 3,4-dihydroxybenzylamine upon human and murine melanoma cells. When exponentially growing cells were exposed to these drugs, a characteristic inhibition of thymidine incorporation was observed with much less inhibition of either uridine or leucine incorporation. In order to ascertain that inhibition was occurring at the level of DNA synthesis, we examined the effects of the drugs upon the incorporation of thymidine triphosphate by permeabilized melanoma cells. When melanoma cells were permeabilized by lysolecithin, thereby permitting the direct incorporation of labeled thymidine triphosphate, a similar inhibition of incorporation was observed. Dopamine at a concentration of 4.8 microM caused a 50% reduction in incorporation of label. These results suggested that inhibition did occur at the level of DNA synthesis. In the presence of the melanocyte-specific oxidase, tyrosinase, these derivatives are potent inhibitors of isolated DNA polymerase alpha with 50% inhibitory concentrations between 1 and 10 microM. The inhibition could be completely prevented by the presence of reducing agents such as dithiothreitol (1.0 mM). The quinols themselves were not inhibitors of DNA polymerase. Dopamine analogs represent an interesting class of antitumor agents with inhibitory activity for DNA polymerase.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6768447

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Comparative cytotoxicity of phenols in vitro.

Authors:  S Passi; M Picardo; M Nazzaro-Porro
Journal:  Biochem J       Date:  1987-07-15       Impact factor: 3.857

2.  Possible genotoxicity of melanin synthesis intermediates: tyrosinase reaction products interact with DNA in vitro.

Authors:  M Miranda; D Botti; M Di Cola
Journal:  Mol Gen Genet       Date:  1984

Review 3.  Neuroendocrine influences on cancer biology.

Authors:  Premal H Thaker; Anil K Sood
Journal:  Semin Cancer Biol       Date:  2007-12-08       Impact factor: 15.707

4.  Antitumor effect of i.p. dopamine in mice bearing Ehrlich ascites carcinoma.

Authors:  P S Dasgupta; T Lahiri
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

5.  Synthesis of cysteinylphenol, cysteaminylphenol, and related compounds, and in vivo evaluation of antimelanoma effect.

Authors:  S Miura; T Ueda; K Jimbow; S Ito; K Fujita
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

6.  A marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment.

Authors:  B Fornstedt; A Carlsson
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

Review 7.  Role of dopamine in malignant tumor growth.

Authors:  S Basu; P S Dasgupta
Journal:  Endocrine       Date:  2000-06       Impact factor: 3.925

8.  The killing effects of 4-S-cysteinylcatechol and analogues on human melanoma cells.

Authors:  I Yamada; S Seki; S Ito; O Matsubara; S Suzuki; T Kasuga
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

9.  The effect of L-dopa on the potentiation of radiation damage to human melanoma cells.

Authors:  I Yamada; S Seki; S Ito; S Suzuki; O Matsubara; T Kasuga
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

10.  The killing effect of 4-S-cysteaminylphenol, a newly synthesised melanin precursor, on B16 melanoma cell lines.

Authors:  I Yamada; S Seki; S Ito; S Suzuki; O Matsubara; T Kasuga
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.